Cargando…
Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
SIMPLE SUMMARY: Drug resistance is a major issue in brain tumor therapy. Despite novel promising therapeutic approaches, glioblastoma (GBM) remains refractory in showing beneficial responses to anticancer agents, as demonstrated by the failure in clinical trials of small kinase inhibitors. One of th...
Autores principales: | Fabro, Federica, Lamfers, Martine L. M., Leenstra, Sieger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833415/ https://www.ncbi.nlm.nih.gov/pubmed/35158868 http://dx.doi.org/10.3390/cancers14030600 |
Ejemplares similares
-
Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
por: Fabro, Federica, et al.
Publicado: (2022) -
Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
por: Ntafoulis, Ioannis, et al.
Publicado: (2022) -
Recent advances in the molecular understanding of glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2012) -
The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014) -
The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)